NH ( patient)
NH ( patient)
NH ( patient)
Only natural ingredients
Only natural ingredients
Only natural ingredients
US FDA 2016
US FDA 2016
US FDA 2016
In connection with publication on MPPT, the
In connection with publication on MPPT, the
In connection with publication on MPPT, the
VH (patient)
VH (patient)
VH (patient)
Micropore Particle Technology - MPPT
Next-generation wound anti-infective acting through the microbiome
Amicapsil (Acapsil) for humans
Surgical wounds, diabetic foot ulcers, venous leg ulcers, pressure ulcers, trauma wounds, burns, etc.
SertaSil for animals
Surgical wounds, bite wounds, puncture wounds, abrasions, lacerations, avulsions/degloving wounds, pressure sores, burns, etc.
Aprobaxil for humans
Acne, hidradenitis suppurativa, atopic dermatitis, psoriasis, pyoderma gangrenosum, boils, furuncles, carbuncles, abscesses, zits etc.
Adinasil for animals
Eczema, dermatitis, granuloma, insect bites, autoimmune skin conditions and others
News
Amicapsil-SCI approved in UK and EU. Amicapsil-SCI is a treatment for wounds and pressure ulcers in SCI-persons and in immunocompromised individuals.
Canadian Spinal Injury Association British Columbia features Amicapsil in its Winter magazine.
Wounds and pressure ulcers in SCI-persons
A new study has shown that MPPT (Amicapsil) is effective in treating wound infections in individuals with spinal cord injury (SCI).
1) Grade 1-4 wounds and pressure ulcers less than 2 months old, all achieved stable closure.
2) All grade 3 ulcers, also older, closed, but it could take longer to achieve this as the infection was more settled into the tissue.
3) Grade 4 wounds without osteomyelitis more than 6 months old would close, but time to reach closure would depend upon the extent and type of infection.
4) Grade 4 wounds with osteomyelitis would reduce substantially in size to being a narrow exit tract through which infectious material from the bone could escape.
5) By reducing soft tissue infection frequency and severity of autonomic dysreflexia were reduced.
Read about MPPT (Amicapsil) and the treatment of wounds and pressure ulcers in SCI-persons.
MPPT can be used for
♦ Closure of wounds that cannot be sutured
♦ Preparing an area for surgery by removing soft-tissue infection in the area
♦ Removing reminants of a diffuse tissue infection and supporting wound healing following surgery
♦ Antibiotic resistant wound infections
♦ Preventing infection in a wound, e.g. trauma or surgical wounds
♦ Inflammatory conditions with disruption of epithelial barriers in the skin
Storage
MPPT is temperature sensitive and needs to be stored refrigerated.
MPPT - only product on the market that in itself has been approved as a "treatment for wounds".
All other technologies used in the treatment of wounds have been approved as "tools or aids to be used in wound care", e.g. for the absorption of wound exudate and it is then assumed that this will have a positive impact on the wound healing process. The permission to claim MPPT to be a treatment with a therapeutic effect separates it from dressings, creams etc. and places it in a category comparable to pharmaceuticals. This permission was given based on the strong clinical data package and safety profile.
”It’s not too much of an exaggeration to say Amicapsil changed my life. From 4 weeks of absolute hell, in pain 24 hours a day, struggling at work and looking at possibly taking time off – to being pain-free, getting a full night’s sleep and back to normal at work.” NH